-
Uncategorized2 months agoLive: Robert F. Kennedy Jr. testifies before Senate HELP committee
Health secretary Robert F. Kennedy Jr. will testify Wednesday before the Senate lawmakers who arguably hold the most power in advancing or hindering his Make America...
-
Uncategorized2 months ago
Pharma-backed petition calls on FDA to reform release of drug rejection letters
The FDA for the first time is facing pharma-backed criticism of its new practice of publicly releasing partially redacted drug rejection letters. The law firm Covington...
-
Uncategorized2 months ago
Viral Contamination Still a Challenge for CGT Industry
Raw material testing will remain the foundation of cell and gene therapy (CGT) sector quality control strategies for the foreseeable future, according to new analysis, which...
-
Uncategorized2 months ago
Revolution drug shows promise in early pancreatic cancer
The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.
-
Uncategorized2 months ago
Nektar’s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs
Nektar Therapeutics prices $325 million public offering: The Bay Area biotech is selling about 3.5 million shares of stock at $92 per share. The proceeds will...
-
Uncategorized2 months ago
Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy
Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy
-
Uncategorized2 months agoModerna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage...
-
Uncategorized2 months ago
Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients
With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead...
-
Uncategorized2 months ago
Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the...
-
Uncategorized2 months agoTipping the genomic scales: Preparing for the integrated multiomics era
This paid-for advertorial by Sampled appeared in DDW Volume 27 – Issue 2, Spring 2026 How sequencing innovation and integrated workflows are enabling reproducible multiomic studies. Genomics has...
Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model
SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines
